Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

European Journal of Cancer Part A

Volumn 33, Issue 2, 1997, Pages 214-219

  De Gramont, A ^a   Vignoud, J ^b   Tournigand, C ^a   Louvet, C ^a   Andre T ^c   Varette, C ^a   Raymond, E ^a   Moreau, S ^a   Le Bail, N ^b   Krulik, M ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b DEBIOPHARM France   (France)

^c HÔPITAL TENON   (France)

Author keywords

5 FU infusion; Colorectal cancer; Folinic acid (leucovorin); Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; FEMALE; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030888321     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00370-X     Document Type: Article

References (32)

1. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma, a mid-Atlantic oncology program study. J Clin Oncol 1989, 7, 425-432.
2. Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal cancer and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986, 4, 685-696.
3. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987, 5, 1559-1565.
4. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorecal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
5. Budd GT, Fleming TR, Bukowski JD, et al. 5 Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer, a randomized comparison. A southwest oncology group study. J Clin Oncol 1987, 5, 272-277.
6. de Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Oncol 1988, 24, 1499-1503.
7. de Gramont A, Bosset JF, Milan C, et al. A prospectively randomized trial comparing 5-FU bolus with low-dose folinic acid and 5-FU bolus plus continuous infusion with high-dose folinic acid for advanced colorectal cancer. Proc Am Soc Clin Oncol 1995, 14, 194.
8. Ardalan B, Chua L, Tiang E, et al. A phase II of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal cancer. J Clin Oncol 1991, 9, 625-630.
9. de Gramont A, Thirion P. Rational for high-dose folinic-acid and 5-fluorouracil in short continuous infusion in colorectal cancer. Continuous Infusion Newsletter 1994, 2, 8-15.
10. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumour activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II), new experimental data. Biomed Parmacother 1989, 43, 251-260.
11. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning and bioformation of oxaliplatin. Cancer Res 1993, 53, 5970-5976.
12. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 1988, 48, 9-13.
13. Moreau S, Machover D, de Gramont A, et al. Phase II trial of oxaliplatin (L-OHP) in patients with colorectal carcinoma previously resistant to 5-fluorouracil and folinic acid. Proc Am Soc Clin Oncol 1993, 12, 214.
14. Diaz Rubio E, Marty M, Extra JM, et al. Multicentric phase II study with oxaliplatin (L-OHP) in 5-FU refractory patients with advanced colorectal cancer. Fifth International Congress on Anti-Cancer Chemotherapy. Paris, February 1995. Abstract 0721, 161.
15. Mathé G, Kidani Y, Segiguchi M, et al. Oxalatoplatinum or 1-OHP, a third generation platinum complex, an experimental and clinical appraisal and preliminary comparison with cisplatin and carboplatinum. Biomed Parmacother 1989, 43, 237-250.
16. Lévi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992, 69, 893-900.
17. Lévi F, Zidani R, di Palma M, et al. Improved therapeutic index through ambulatory circadian rhythmic delivery (CRD) of high-dose 3-drug chemotherapy in a randomized phase III multicenter trial. Proc Am Soc Clin Oncol 1994, 13, 197.
18. de Gramont A, Gastiaburu J, Tournigand C, et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 h infusion in pretreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1994, 13, 220.
19. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Genova, WHO, 1979.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
21. Mori A, Bertoglio S, Guglielmi A, et al. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993, 33, 179-180.
22. de Gramont A, Louvet C, Bennamoun M, et al. Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. J Infusional Chemother 1996, 6, 97-101.
23. Bugat R, Rougier P, Douillard JY, et al. Efficacy of irinotecan HCl (CPT11) in patients with metastatic colorectal cancer after progression while receiving a 5-FU-based chemotherapy. Proc Am Soc Clin Oncol 1995, 14, 222.
24. Extra JMP, Espie M, Calvo F, Fermé C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990, 25, 299-303.
25. Lévi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous infusion at circadian rhythm modulated rate. Eur J Cancer 1993, 9, 1280-1284.
26. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7, 95-98.
27. Gale GR, Atkins LM. Synergistic action of high-dose hydroxyurea when used with cyclophosphamide and certain new organoplatinum complexes in treatment of advanced L1210 leukemia. Cancer 1978, 41, 1230-1234.
28. Raymond E, Goldwasser F, Djelloul S, Buquet-Fagot C, Cvitkovic E, Gespach C. A rationale for oxaliplatin-based combinations in colon cancer. 9th NCI-EORTC Symposium, Amsterdam 12-15 March 1996. Abstract 236.
29. Brienza S, Lévi F, Valori VM, et al. Intensified (every 2 weeks) chronotherapy with 5-fluorouracil, folinic acid and oxaliplatin in previously treated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993, 12, 197.
30. Berteault-Cvitkovic F, Jami A, Itzakhi M, et al. Dose intensification of circadian-rhythm modulated 5-fluorouracil combined with oxaliplatin and folinic acid against metastatic colorectal cancer. A feasibility study. Proc Am Soc Clin Oncol 1994, 13, 217.
31. Garufi C, Brienza S, Misset JL. Addition of oxaliplatin to chronomodulated 5-fluorouracil and folinic acid for reversal of acquired chemoresistance in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1995, 14, 192.
32. Brienza S, Fandi A, Hugret F, et al. Neurotoxicity of long term oxaliplatin (L-OHP) therapy. Proc Am Ass Cancer Res 1993, 34, 406.